

# Enoxaparin Biosimilars

Micheal Guirguis & Tony Nickonchuk  
Drug Utilization & Stewardship

# Background

- Enoxaparin added to Alberta Biosimilar Initiative July 1, 2021
- AHS received proposals from Sanofi (Lovenox<sup>®</sup>), Juno (Noromby<sup>®</sup>) and Valeo (Redesca<sup>®</sup>)
- After review, contract was awarded to Juno (Noromby<sup>®</sup>) for prefilled syringes and to Valeo (Redesca<sup>®</sup>) for multi-dose vial

# Noromby®

- Will replace all current Lovenox® prefilled syringe strengths on formulary
- 30 mg, 40 mg, 60 mg, 80 mg, 100 mg, 120 mg, & 150 mg

# Noromby®

- Educational Tools available at:  
AHS Drug Stewardship -  
[www.ahs.ca/drugstewardship](http://www.ahs.ca/drugstewardship)
- Demo syringes: Contact Ky To  
with Juno at  
[kyto@junopharm.com](mailto:kyto@junopharm.com)

# Redesca<sup>®</sup>

- Juno does not offer a multi-dose vial, but Valeo does
- Will replace Lovenox<sup>®</sup> 300 mg/3 mL multi-dose vial on formulary

# Formulary Restrictions

- Biosimilar products must be used for all new starts for formulary approved indications for enoxaparin

# Biologic Exception

- Brand name Lovenox<sup>®</sup> is restricted to patients stabilized on it prior to admission who ALSO have a biologic exception from Alberta Blue Cross

**Thanks!**

**Micheal.Guirguis@ahs.ca**

**Tony.Nickonchuk@ahs.ca**